adaptive immune responses. The class II transactivator (CIITA in human and C2TA in mouse) is the master regulator of MHC-II gene expression. It coordinates the transcription factors necessary for the transcription of MHC-II molecules. In humans, genetic variations in CIITA have been associated with differential expression of MHC-II and susceptibility to autoimmune diseases. Here we made use of a C2ta congenic mouse strain (expressing MHC-II haplotype H-2 q ) to investigate the effect of the natural genetic polymorphisms in type I promoter of C2ta on MHC-II expression and function. We demonstrate that an allelic variant in the type I promoter of C2ta resulted in an increased expression of MHC-II on macrophages (72-151% higher mean florescence intensity) and conventional dendritic cells (13-65% higher mean florescence intensity) in both spleen and peripheral blood. The increase in MHC-II expression resulted in an increase in antigen presentation to T cells in vitro and increased T-cell activation. The differential MHC-II expression in B6Q.C2ta, however, did not alter the disease development in models of rheumatoid arthritis (collagen-induced arthritis and human glucose-6-phosphateisomerase 325-339 -peptide-induced arthritis), or multiple sclerosis (MOG protein-induced and MOG 79-96 peptide-induced experimental autoimmune encephalomyelitis). This is the first study to address the role of an allelic variant in type I promoter of C2ta in MHC-II expression and autoimmune diseases; and shows that C2ta polymorphisms regulate MHC-II expression and T-cell responses but do not necessarily have a strong impact on autoimmune diseases.
Introduction
The MHC region encodes peptide receptors that are the critical molecules for activation of antigen-specific T cells. The MHC region is in strong linkage disequilibrium and with a pronounced polymorphism of critical importance for the immune response. Importantly, it is strongly associated with autoimmune diseases, consistently shown in multiple genome-wide association studies (GWAS) analyses. Well-studied autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA) and type I diabetes (T1D) are all strongly associated with MHC-II DR alleles, encoding MHC class II (MHC-II) chains. [1] [2] [3] [4] These diseases are characterized by a chronic inflammatory, autoimmune process directed towards certain tissues and organs such as central nervous system (MS), joints (RA), or insulin-producing beta cells (T1D). Over 100 risk loci have been identified in both MS and RA with the main contribution from the MHC genes and minor contribution from non-MHC genes. [1] [2] [3] Although the strong associations with MHC-II genes have been recognized for several decades, [5] [6] [7] [8] the high gene density, extreme polymorphism and strong linkage disequilibrium of the MHC region have hampered the identification of variants driving these associations. 
I M M U N O L O G Y O R I G I N A L A R T I C L E
MHC-II expression is controlled mainly at the level of transcription, by a complex consisting of a regulatory module known as the SXY module and multiple transcription factors. 9 The class II transactivator (CIITA) interacts with this multiprotein complex and coordinates the recruitment of additional factors important for chromatin modification, remodelling, and also transcription initiation and elongation. 9 There are four CIITA isoforms in humans (pI, pII, pIII and pIV), 10 and three in mice and rats (pI, pIII and pIV with promoter type I, III and IV). Isoform pI mainly controls C2ta expression on cells of myeloid lineage, including macrophages and dendritic cells; pIII regulates C2ta expression on B cells and plasmacytoid dendritic cells; 11 and pIV regulates C2ta expression on thymic epithelial cells. 12 Genetic variations in C2TA have been associated with susceptibility to multiple autoimmune diseases in both humans and rodents. It was first identified in a genetic analysis of an advanced intercross line in rats that polymorphisms in the 5 0 flanking region of C2ta explain straindependent differences in expression of MHC-II molecules. 13 It was later shown in the congenic strains in rats that the C2ta polymorphisms alter susceptibility to experimental autoimmune encephalomyelitis (EAE), a chronic relapsing model of MS.
14 The experimental findings in rats prompted further investigation of C2TA in humans and it was demonstrated that a single nucleotide polymorphism in the 5 0 flanking region of type III promoter of C2TA is associated with susceptibility to RA, MS and myocardial infarction.
13
C2TA disease association has since then been shown in different patient cohorts in not only RA 15, 16 and MS, 17, 18 but also T1D, 19 coeliac disease 20 and systemic lupus erythematosus, 21, 22 although disease associations could not be reproduced in some populations. [23] [24] [25] In this study, we generated a C2ta congenic mouse strain to investigate the effect of an allelic variant of C2ta promoter on MHC-II expression in different antigen-presenting cells (APCs). We then assessed the functional implications of the resulting MHC-II expression difference on antigen presentation of the immune cells in the congenic versus wild-type control (wt) mice. To understand if this C2ta-driven MHC-II expression difference modulates autoimmunity, we selected models that have previously been shown to be controlled by the MHC-II locus and in particular by the A q gene; 26 i.e. EAE, collagen-induced arthritis (CIA) and human glucose-6-phosphate-isomerase (hG6PI) 325-339 -peptide-induced arthritis in these mice.
Materials and methods

Animal experimentation
Mice were bred and maintained in a barrier facility at Scheele Laboratory, Karolinska Institutet, and were specific pathogen-free according to the Federation of European Animal Laboratory Science Associations guidelines. All animals were housed in a climate-controlled environment with 14 hr light/10 hr dark cycles, in individually ventilated microisolator-cages (Allentown Inc. Allentown, NJ) containing wood shavings (Tapvei, Scanbur, Sollentuna, Sweden), and fed standard rodent chow (R70, Lantm€ annen, Stockholm, Sweden) and had free access to water. Age-and sex-matched, 9-14 weeks old, congenic and wt control mice have been used in all experiments, unless otherwise specified. All experiments were carried out with littermate controls and mice of different groups were mixed in cages. All experiments were performed with the identity of the mice blinded for the investigator. All experiments were approved by the Stockholm Ethical Committee and performed in accordance with the guidelines of the Swedish National Board for Laboratory Animals and the European Community Council Directive (86/609/EEC).
Mice
Congenic fragment containing the C2ta locus originated from 129X1/SvJ mice and was first backcrossed to C57BL/6J (MHC-II haplotype H-2 b ) for 12 generations. The congenic fragment was subsequently backcrossed to C57BL/6N.Q (short-named B6Q, MHC-II haplotype H-2 q ) 27 to generate mice with the homozygous expression of the MHC-II A q . The maximum size of the introgressed fragment is roughly 10Á2 Mb, spanning from 5Á68 Mb (marker D16Mit182) to 15Á91 Mb (marker D16Mit34), congenic mice are denoted B6Q.C2ta. Female mice used in CIA experiments were ovariectomized before immunization to increase their susceptibility to arthritis. 28 
Genotyping
Genomic DNA was extracted from progeny biopsies for genotyping. 29 Forward primers were fluorescently labelled, and genomic DNA was amplified with PCR according to a standard protocol and analysed on a 48-capillary ABI 3730 DNA analyser (Applied Biosystems, Foster City, CA) as previously described. 29 Harvest and culture of bone marrow-derived macrophages
Mouse bone marrow cells were obtained from both femurs in PBS, filtered through a 40-lm filter and resuspended in in Dulbecco's modified Eagle's medium (Gibco, Carlsbad, CA) supplemented with 10% (vol/vol) fetal calf serum (Gibco), 50 lM b-mercaptoethanol (Gibco), 10 mM HEPES (Gibco), 10 U/ml penicillin and 100 lg/ml streptomycin (both from Invitrogen Life Technologies, Carlsbad, CA). Cells were cultured at a density ª 2016 John Wiley & Sons Ltd, Immunology, 150, 408-417 of 1 9 10 6 /ml in 100 9 20 mm cell-culture plates with 20 ng/ml murine macrophage colony-stimulating factor (Peprotech, Rocky Hill, NJ) for 6 days at 37°in 5% CO 2 . The medium was renewed on day 3. Cells were subsequently stimulated with 0, 1 and 10 ng/ml interferon-c (Peprotech) for 24 hr at 37°in 5% CO 2 .
Antigen presentation assay
Spleens were harvested from untreated mice and singlecell suspensions were prepared by mechanical disruption of spleen and filtered through a 40-lm filter. Either 1 9 10 5 or 2 9 10 5 splenocytes were plated per well of a 96-well plate (Nunc, Roskilde, Denmark) in Dulbecco's modified Eagle's medium supplemented with 5% (vol/ vol) fetal calf serum, 50 lM b-mercaptoethanol, 10 mM HEPES, 10 U/ml penicillin, and 100 lg/ml streptomycin. HCQ.3 hybridoma T cells (5 9 10 4 ), specific for the CII256-270 (Gal-264) peptide bound to MHC-A q , 30 as well as CII peptide, were added to each well. CII peptides, containing the 259-273 sequence of rat CII with a b-Dgalactopyranosyl residue on L-hydroxylysine at position 264, were synthesized as previously described. 31 After 24 hr of culturing at 37°in 5% CO 2 , the supernatants were analysed for interleukin-2 by sandwich ELISA.
Cytokine ELISA
To determine the concentration of interleukin-2 in the supernatant, 50 ll supernatant was removed from the plates after 24 hr of culture. JES6-IA12 (2 lg/ml, homemade) and JES6-5H4-biotin (1 lg/ml, Mabtech, Nacka Strand, Sweden) were used as capture antibody and detection antibody, respectively. Eu 3+ -conjugated streptavidin (DELFIA) was used for detection, performed on a Synergy 2 multi-mode plate reader (BioTek, Winooski, VT).
EAE induction and evaluation
Experimental autoimmune encephalomyelitis was induced by intradermal injection of 20 lg myelin oligodendrocyte glycoprotein (MOG) or 50 lg MOG 79-96 peptide emulsified in complete Freund's adjuvant (Difco, Detroit, MI) at the base of the tail. For EAE induction by MOG 79-96 peptide, 400 ng pertussin toxin was injected intravenously on day 0 and day 2. For EAE induction by MOG protein, 200 ng pertussin toxin was injected intravenously on day 0 and day 2. Recombinant rat MOG (amino acids 1-125 from the N terminus) was expressed in Escherichia coli and purified to homogeneity by chelate chromatography. 32 EAE was monitored on a scoring scale as follows: 0 = normal; 1 = tail weakness; 2 = tail paralysis; 3 = mild waddling movement; 4 = heavy waddling movement, unsecure foothold; 5 = paralysis of a limb, crawling; 6 = paralysis of a pair of limbs; 7 = paralysis of all four limbs; 8 = death. Animals were euthanized when they reached score 7.
Arthritis induction and evaluation
Collagen-induced arthritis was induced by intradermal injection of 100 lg of rat type II collagen (CII), prepared as described earlier, 33 emulsified in complete Freund's adjuvant (Difco) at the base of the tail. After 35 days, mice were boosted with 50 lg of CII in incomplete Freund's adjuvant (Difco) at the same site. The hG6PI-induced arthritis was induced by intradermal injection of 10 lg hG6PI 325-339 -peptide emulsified in complete Freund's adjuvant (Difco) at the base of the tail 39 . Arthritis development was quantified using a macroscopic scoring system; one point was given for each swollen or red toe or joint and five points for a swollen ankle, adding up to a maximum score of 60 points per mouse.
Flow cytometry
Single-cell suspensions were prepared in ice-cold FACS buffer (Ca 2+ -free and Mg 2+ -free Dulbecco's PBS supplemented with 1% fetal calf serum, 10 mM EDTA), with subsequent lysing of erythrocytes. Both splenocytes and heparinized peripheral blood were incubated with 2.4G2 antibody for FccR-blockade and stained with a saturating concentration of monoclonal antibodies on 96-well V-bottom polypropylene plates (BD Biosciences, San Jose, CA). The following antibodies were used: CD90.2 (Thy1.2), CD45R (B220), I-A/I-E (2G9) and CD11c (N418), purchased from BD Biosciences. CD11b (M1/ 70), Gr-1 (RB6-8C5) and F4/80 (BM8) were purchased from (BioLegend, San Diego, CA). Both LIVE/DEAD (Invitrogen) and the forward-scatter versus side-scatter plot were used to include only non-necrotic cells. A SORP BDLSR II analytic flow cytometer (BD Biosciences, San Jose, CA) was used for acquisition, and the data were analysed with FLOWJO (Tree Star, Ashland, OR).
Statistical analysis
All statistical analyses were evaluated by Mann-Whitney U-test using GRAPHPAD PRISM 6.0 software (San Diego, CA). Results are considered significant for P < 0Á05.
Bioinformatics
The sequence of the type I promoter of C2ta, 1000 bp upstream from the transcriptional start site, was retrieved from UCSC Genome Browser (GRCm38/mm10) Assembly. Regulatory factor binding prediction was performed by CONREAL.
Results
Effect of genetic polymorphisms in C2ta on MHC-II expression in B6NQ.C2ta congenic mice It has previously been shown 35 that there are three singlenucleotide polymorphisms (SNPs) in the type I promoter of C2ta (C57BL/6 versus 129X1/SvJ), which are located at À715, À712 and À402 relative to the transcriptional start site. A bioinformatic analysis of this region using CON-REAL 34 showed that these polymorphic sites could potentially be the binding sites of various regulatory factors, such as nuclear transcription factor and cAMP response element-binding protein (CREB) (see Supplementary material, Fig. S1 ). Binding of CREB to the regulatory region of CIITA has been suggested to play important roles in the activation of CIITA-PIII in B cells. 36 Since C2TA acts as a master regulator of MHC class II, we next assessed the impact of these genetic polymorphisms in the C2ta promoter on MHC-II expression. The MHC-II expression differs between the APCs (Fig. 1) and depends on the immune conditions, for example, MHC-II expression on macrophages can be stimulated by the presence of interferon-c. 37 By flow cytometric analysis of splenocytes and peripheral blood from the B6Q.C2ta congenic and B6Q wt mice, we determined the surface MHC-II expression on monocytes/macrophages (CD11b (Fig. 1a) . We found that, in the spleen, the B6Q.C2ta congenic mice showed a significantly increased MHC-II expression on monocytes/macrophages (72-110% higher), conventional dendritic cells (65% higher) and plasmacytoid dendritic cells (38% higher) compared with the B6Q wt mice (Fig. 1b-e) . In the blood, elevated MHC-II expression was similarly found on the monocytes/macrophages (117-151% higher) and conventional dendritic cells (13% higher) from the B6Q.C2ta congenic mice (Fig. 1b-d) . There was, however, no difference in the MHC-II expression on B cells obtained from spleen or blood (Fig. 1f) . We further investigated if the increased MHC-II expression in spleen and blood was also observed in bone-marrow-derived macrophages. We found that the B6Q.C2ta congenic mice displayed an increased MHC-II expression on the bone-marrow-derived macrophages (29-37% higher) (Fig. 1g) , indicating that the allelic differences in C2ta in the B6Q.C2ta congenic mice have a profound impact on MHC-II expression in both central and peripheral lymphoid organs.
Increased antigen presentation when co-cultured with HCQ.3 hybridoma T cells
Having shown higher MHC-II expression in B6Q.C2ta congenic mice, we investigated whether this could lead to different antigen presentation to T cells in vitro, resulting in altered T-cell activation. To achieve this, we performed an antigen presentation assay using rat type II collagen peptide (CII 259-273 ) with a b-D-galactopyranosyl residue on L-hydroxylysine at position 264 as the antigen. 31 We used splenocytes from naive B6Q.C2ta congenic and B6Q wt mice as a source of APCs and we cultured these splenocytes with HCQ.3 hybridoma T cells, which are specific for the glycosylated form of the CII 256-270 peptide bound to MHC-II A q . 30 After 24 hr, the concentration of interleukin-2 in the supernatant was determined as a measure of T-cell activation. We found that APCs from B6Q.C2ta mice induced significantly higher levels of interleukin-2 production, compared with B6Q wt mice (Fig. 2a-b) . These results indicate that the higher MHC-II expression on APCs in B6Q.C2ta congenic mice could lead to increased antigen presentation to T cells in vitro and that allelic differences in C2ta could lead to quantitative differences in antigen presentation.
No difference in CIA and hG6PI-induced arthritis
Considering the association between both CIITA and MHC-II with RA, 6, 7, 13 we investigated the effect of C2ta alleles on CIA, one of the most commonly used animal models for RA. To facilitate investigation of the effect of C2ta alleles in different models of autoimmune diseases, the congenic fragment C57BL/6J.129 was backcrossed to C57BL/6N.Q to generate a homozygous MHC-II H-2 q haplotype, which is susceptible to both CIA, hG6PI-induced arthritis and EAE (C57BL/6N.Q.129, denoted as B6Q.C2ta). 31, 38, 39 We found that B6Q.C2ta congenic and B6Q wt mice developed comparable CIA with no difference in both daily arthritis score and cumulative arthritis score (Fig. 3a,  b) ; and similar results were obtained in both male and female mice ( Table 1) . As age is known to affect the susceptibility of mice to develop arthritis, 40 we performed the same experiment also in older mice (20-24 weeks old). We found that older mice developed more severe arthritis. However, similar to the younger mice (9-14 weeks old), both B6Q.C2ta congenic and B6Q wt mice developed comparable CIA (Table 1) . We next investigated if C2ta polymorphisms regulate hG6PI 325-339 -peptide-induced arthritis, a new arthritis model dependent on MHC-II, T and B cells, as well as complement factor C5. 39 Similarly, the B6Q.C2ta congenic mice developed arthritis as severe as the B6Q wt mice with no difference in both daily arthritis score and cumulative arthritis score (Fig. 3c-d) .
Comparable disease development in EAE
We investigated whether MHC-II expression difference on macrophages and dendritic cells and the subsequent increase in antigen presentation regulate susceptibility to autoimmune neuroinflammation. This is interesting especially since naturally occurring allelic differences in C2ta have been shown to regulate susceptibility to EAE in rats. 14 We induced EAE in both B6Q.C2ta congenic and B6Q wt mice by immunization of either MOG 1-125 protein or MOG 79-96 peptide, both known to induce EAE in H-2 q mice. 38 In contrast to the findings in the Vra4 congenic rats, 14 there was no difference in both the disease score and weight change between the B6Q.C2ta congenic and B6Q wt mice in both MOG protein-induced EAE (Fig. 4a-c) and MOG 79-96 peptide-induced EAE (Fig. 4d-f) . Similar results were found in both male and female mice ( Table 2) . 
Gated on live, non-B, non-T cells Gated on live, non-T cells Gated on live, non-T cells
Discussion
We demonstrate here that an allelic difference in C2ta gene exerts an important regulatory effect on MHC-II expression of the B6Q.C2ta congenic mice. These findings were achieved by using congenics, isolating a C2ta congenic fragment from the donor strain 129X1/SvJ onto a recipient C57BL/6N.Q background. The mice also Denotes the number of animals in the group. 4 Female mice were ovariectomized before immunization to increase susceptibility to arthritis. expressed the MHCII A q gene, allowing studies of the effect of C2ta in different experimental models of MS and RA. 31, 38, 39 The CIITA gene is of particular importance since the encoded protein functions as an assembler of transcription factors necessary for the transcription of MHC-II molecules. There are three C2ta isoforms in mouse (pI, pIII and pIV with promoters type I, III and IV) and the regulatory region of the C2ta gene was previously sequenced in multiple inbred strains. 35 Only type I promoter, but not type III and type IV promoters, is polymorphic between C57BL/6 and 129X1/SvJ. 35 These polymorphisms resulted in significantly higher C2ta, Cd74 and pI expression in the congenic strains carrying the 129X1/SvJ C2ta allele on a B6 background, compared with parental controls. 35 Here we showed that an allelic variant in the type I promoter of C2ta led to differential MHC-II expression in both macrophages and conventional dendritic cells in both spleen and peripheral blood, consistent with the known function of type I promoter in controlling C2ta expression in cells of myeloid lineage. We further showed that an increased MHC-II expression in the B6Q.C2ta congenic mice has a regulatory effect on the antigen presentation to T cells and resulted in an increased T-cell activation in vitro.
The importance of CIITA gene is shown by the fact that loss of function of the CIITA gene due to splicing mutation can result in bare lymphocyte syndrome, leading to a severely compromised immune system and inability to fight infection. 41 Chromosomal translocation of CIITA has been linked to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma. 42 Genetic variations in the CIITA gene have also been associated with several autoimmune disorders in humans, including RA, 13 20 and systemic lupus erythematosus. 20, 21 Different SNPs have been associated with these diseases, including rs3087456 in the type III promoter of CIITA, an intronic SNP rs8048002, and rs4774, which is a missense mutation resulting in an amino acid change from glycine to alanine. 13, 15, 18 The -168A/G polymorphism (rs3087456) in the type III promoter of CIITA is one of the most investigated for disease association in humans. The pIII C2ta has also been investigated in rats in a congenic setting and has been previously shown to be associated with EAE.
14 Mice with a knockout in pIV C2ta, however, were found to not influence the development of CIA. 43 To our knowledge, genetic variants in the type I promoter of CIITA have not been shown for association with autoimmune disorders in humans and this is the first time a natural genetic variant in the type I promoter of C2ta has been evaluated for regulatory roles in immune response and in autoimmune diseases. Our data showed that increased MHC-II expression on macrophages and conventional dendritic cells as a result of polymorphisms in the type I promoter of C2ta influence T-cell activation. Surprisingly, however, we could not show any effect on T-cell-dependent autoimmune disease models. Abrogation of MHC-II expression on fibroblastlike synoviocytes in pIV À/À K14 CIITA-transgenic mice likewise also has no impact on experimental arthritis. 43 However, quantitative difference in MHC-II expression on B cells may have a small but significant impact on autoimmunity, as shown in the Vra4 congenic rats, which displayed significantly lower MHC-II expression on B cells and are protected from EAE. 14 This is interesting considering that recent evidence has suggested that B cells may play more important pathogenic roles than previously anticipated, both as precursors of antibody-producing plasma cells and as APCs for the activation of T cells in MS; 44 and in the success of B-cell depletion therapy such as anti-CD20 treatment in rapidly reducing the formation of new inflammatory central nervous system lesions in MS. 45 As the locus with the strongest association to the susceptibility of many autoimmune diseases, the genetic association of the MHC has been extensively studied in both MS 1 and RA. 46, 47 In both RA and MS, the HLA-DRB1 gene contributes the largest genetic variance among all risk genes, 46, 48 although the pathogenic mechanisms of MHC-II in MS and RA are not the same: HLA-DRB1*15:01 has the strongest effect in MS; 1 HLA-DRB1*04:01, *04:04 and *01:01 are the most frequent RA risk alleles in European populations. Whereas the effects of MHC-II coding variants on MS and RA have been studied in more depth, the impact of quantitative differences in MHC-II expression on autoimmune diseases has not been as extensively studied. We recently investigated this using a panel of MHC-II Tcs2 congenic rat strains that displayed variation in severity in pristane-induced arthritis. 49 We found that variation in arthritis severity between the Tcs2 congenic rat strains could not simply be explained by the MHC-II expression difference on APCs. The disease variation was in fact mainly explained by the coding variants in the P1 pocket of the MHC-II molecules, which subsequently influenced the organization and occupancy of the peptide-binding groove. 49 Hence, both the current and other studies 43, 49 seem to suggest that the level of MHC-II expression plays a relatively minor overall role in the regulation of autoimmune diseases triggered by an exogenous immunization, like EAE and CIA. CIITA is regarded as master regulator of MHC-II genes and induces MHC-II gene transcription in a cell-specific manner. CIITA itself is in fact tightly regulated at a transcriptional level by not only genetic but also epigenetic mechanisms, including methylation of DNA and histone acetylation and methylation modifications. Long-range chromatin interactions are also involved in the transcriptional activation of CIITA. 50 Therefore, there are multiple levels of regulation on CIITA and MHC-II expression which subsequently may have different effects on autoimmunity.
In conclusion, we demonstrate in a congenic mouse setting that genetic polymorphisms in the type I promoter of C2ta regulate MHC-II expression on professional APCs including macrophages and conventional dendritic cells. We showed that the increase in MHC-II expression on APCs led to increased antigen presentation in vitro and increased T-cell activation. These MHC-II expression differences and increased antigen presentation capacity, however, did not have a strong impact on the susceptibility to EAE and experimental arthritis. We believe our findings provide important information on the complex regulation of MHC-II in autoimmunity.
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